share_log

Pfizer Inc. (NYSE:PFE) Shares Acquired by Ritholtz Wealth Management

Pfizer Inc. (NYSE:PFE) Shares Acquired by Ritholtz Wealth Management

辉瑞(纽约证券交易所代码:PFE)被Ritholtz财富管理公司收购的股票
Defense World ·  2022/09/25 21:01

Ritholtz Wealth Management increased its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 22.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 70,807 shares of the biopharmaceutical company's stock after acquiring an additional 12,750 shares during the period. Ritholtz Wealth Management's holdings in Pfizer were worth $3,712,000 at the end of the most recent reporting period.

Ritholtz Wealth Management在提交给美国证券交易委员会的最近一份13F文件中称,该公司在第二季度增持了辉瑞(纽约证券交易所代码:PFE-GET评级)的头寸22.0%。在此期间,该公司额外收购了12,750股票,拥有70,807股这家生物制药公司的股票。在最近一个报告期结束时,Ritholtz Wealth Management持有的辉瑞股份价值3,712,000美元。

Other large investors have also modified their holdings of the company. Baltimore Washington Financial Advisors Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth about $290,000. Rinkey Investments acquired a new position in Pfizer during the 4th quarter valued at about $32,000. Worth Asset Management LLC acquired a new position in Pfizer during the 1st quarter valued at about $29,000. Bivin & Associates Inc. acquired a new position in Pfizer during the 4th quarter valued at about $37,000. Finally, Stuart Chaussee & Associates Inc. increased its stake in Pfizer by 108.3% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 325 shares during the period. Institutional investors and hedge funds own 67.90% of the company's stock.

其他大型投资者也调整了对该公司的持股。巴尔的摩华盛顿金融顾问公司(Baltimore Washington Financial Advisors Inc.)在第四季度增持了辉瑞股份,价值约29万美元。Rinkey Investments在第四季度收购了辉瑞的一个新头寸,价值约3.2万美元。Worth Asset Management LLC在第一季度收购了辉瑞的一个新头寸,价值约2.9万美元。Bivin&Associates Inc.在第四季度收购了辉瑞的一个新头寸,价值约3.7万美元。最后,Stuart Chaussee&Associates Inc.在第一季度增持了辉瑞108.3%的股份。Stuart Chaussee&Associates Inc.在此期间又购买了325股,现在持有这家生物制药公司625股股票,价值3.2万美元。机构投资者和对冲基金持有该公司67.90%的股票。

Get
到达
Pfizer
辉瑞公司
alerts:
警报:

Pfizer Stock Performance

辉瑞股票表现

Shares of PFE opened at $44.08 on Friday. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71. The company has a 50-day moving average of $48.24 and a two-hundred day moving average of $50.32. The stock has a market cap of $247.39 billion, a price-to-earnings ratio of 8.63, a PEG ratio of 0.54 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20.

上周五,PFE的股价开盘报44.08美元。辉瑞公司股价一年来最低为40.94美元,一年最高为61.71美元。该公司的50日移动均线切入位在48.24美元,200日移动均线切入位在50.32美元。该股市值为2,473.9亿美元,市盈率为8.63倍,市盈率为0.54倍,贝塔系数为0.70。该公司的债务权益比为0.39,流动比率为1.42,速动比率为1.20。

Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. The company had revenue of $27.74 billion during the quarter, compared to analysts' expectations of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The business's revenue for the quarter was up 46.8% on a year-over-year basis. During the same period last year, the company posted $1.07 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 6.54 earnings per share for the current year.
辉瑞(NYSE:PFE-GET Rating)最近一次公布财报是在7月28日星期四。这家生物制药公司公布本季度每股收益为2.04美元,比普遍预期的1.95美元高出0.09美元。该公司本季度营收为277.4亿美元,高于分析师预期的262亿美元。辉瑞的净利润率为28.92%,股本回报率为43.18%。该业务本季度的收入同比增长了46.8%。去年同期,该公司公布的每股收益为1.07美元。股票研究分析师平均预计,辉瑞公司本年度每股收益将达到6.54美元。

Pfizer Announces Dividend

辉瑞宣布分红

The business also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.63%. The ex-dividend date of this dividend is Thursday, November 3rd. Pfizer's dividend payout ratio is currently 31.31%.

该公司最近还宣布了季度股息,将于12月5日(星期一)支付。11月4日(星期五)登记在册的投资者将获得每股0.40美元的股息。这意味着年化股息为1.60美元,股息收益率为3.63%。本次股息除息日期为11月3日(星期四)。辉瑞的派息比率目前为31.31%。

Analysts Set New Price Targets

分析师设定新的价格目标

Several equities analysts have commented on the stock. UBS Group set a $59.00 target price on shares of Pfizer in a research note on Thursday, September 1st. Morgan Stanley lowered their target price on shares of Pfizer from $52.00 to $49.00 and set an "equal weight" rating on the stock in a research note on Friday, July 8th. SVB Leerink lowered their target price on shares of Pfizer from $55.00 to $53.00 and set a "market perform" rating on the stock in a research note on Friday, July 29th. Barclays set a $50.00 price objective on shares of Pfizer in a research note on Thursday, September 1st. Finally, JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a research note on Tuesday, June 28th. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $57.00.

几位股票分析师对该股发表了评论。瑞银集团在9月1日周四的一份研究报告中为辉瑞股票设定了59.00美元的目标价。摩根士丹利在7月8日(周五)的一份研究报告中将辉瑞股票的目标价从52.00美元下调至49.00美元,并对该股设定了“同等权重”的评级。SVB Leerink在7月29日周五的一份研究报告中将辉瑞股票的目标价从55.00美元下调至53.00美元,并对该股设定了“市场表现”评级。巴克莱在9月1日周四的一份研究报告中为辉瑞股票设定了50.00美元的目标价。最后,摩根大通在6月28日周二的一份研究报告中为辉瑞的股价设定了57.00美元的目标价。9位股票研究分析师对该股的评级为持有,10位分析师给出了买入评级,一位分析师给出了强烈的买入评级。根据MarketBeat.com的数据,该股目前的共识评级为“适度买入”,共识目标价为57.00美元。

Pfizer Profile

辉瑞简介

(Get Rating)

(获取评级)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

辉瑞在全球发现、开发、制造、营销、分销和销售生物制药产品。该公司在不同的治疗领域提供药物和疫苗,包括Premarin系列和Eiquis品牌的心血管代谢和妇女健康;Ibrance、Xtandi、Sutent、Inlyta、Retacritt、Lorbrena和Braftovi品牌的生物制品、小分子、免疫疗法和生物仿制药;舒必乐、Medrol、Zavicefta、Zithromax、Vfend、Panzyga和Paxlovid品牌的无菌注射和抗感染药物以及口服新冠肺炎治疗。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Pfizer (PFE)
  • Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
  • MarketBeat: Week in Review 9/19 – 9/23
  • Why Does Tesla Stock Remain Resilient?
  • 2 Semiconductor Stocks To Watch For Reversals
  • Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
  • 免费获取StockNews.com关于辉瑞的研究报告
  • 华尔街对Datadog的热情会带来巨大的收益吗?
  • MarketBeat:回顾一周9/19-9/23
  • 为什么特斯拉的股票保持弹性?
  • 需要关注的2只半导体类股走势逆转
  • 小盘股的裁员是楼市的晴雨表吗?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

接受辉瑞日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对辉瑞及相关公司评级的每日简明摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发